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Research questions 
 Among people who inject drugs, do those with experience of homelessness differ in terms of 
risky injecting practices, contact with harm reduction services and incarceration? 
 Among people who inject drugs, do those with experience of homelessness have a higher 
prevalence of hepatitis C exposure? 
 Is any difference in Hepatitis C exposure comparing homeless and non-homeless PWID 
explained by differences in injecting practices, contact with harm reduction, and incarceration? 
Background 
Estimates of the prevalence of hepatitis C infection among homeless people range from 3.9% to 
36.2%, and in most countries the raised prevalence is primarily associated with injecting drug use 
[1]. Among people who inject drugs (PWID), there is evidence that homelessness and unstable 
housing increase the risk of blood-borne virus infection [2].  
There are a number of possible reasons for this. Homelessness is associated with public injecting, 
which can lead to a sense of urgency, reduced care,  reduced access to clean water and washing 
facilities, reduced access to harm reduction interventions and consequently increased risk of 
bacterial and viral infections [3–7]. People who experience homelessness may also use drugs that 
are associated with increased risk. For example, the Needle Exchange Survey Initiative in Scotland 
reported that homelessness was associated with injecting novel psychoactive substances, and that 
using these drugs was associated with increased risk of HCV exposure [8]. A modelling study using 
surveys of PWID showed that 60% of hepatitis C infections could be attributed to homelessness and 
use of crack cocaine [9], however this used data from 2012.  
Most of the more recent data about the risk of hepatitis C in this population are from smaller studies 
in the UK [9] and from studies outside the UK [11]. There is little recent evidence from the UK of the 
hepatitis C risk in those who experience homelessness and inject drugs and which specific risk 
factors are associated with homelessness. 
This study is timely, considering it is in the context of NHS England’s strategy for hepatitis C 
elimination by 2025. A better understanding of hepatitis C exposure and risk factors associated with 
homelessness can provide evidence for health promotion policies. This study will inform the 
development of strategies to achieve the target of hepatitis C elimination in England in the 
populations that are hardest to reach with existing service models. 
Page 2 of 5 
Methods 
We plan to use secondary anonymised data from the Unlinked Anonymous Monitoring Survey of HIV 
and Viral Hepatitis among People Who Inject Drugs (UAMS) [12].The survey is funded, developed 
and managed by Public Health England and has run annually since 1990, with the latest available 
data from 2017. People who inject drugs are recruited via a sample of specialist drug services (such 
as needle and syringe programmes and addiction treatment centres) throughout England, Wales and 
Northern Ireland. 
We plan to use data from the 2012-2017 surveys to achieve a large sample size without using data 
that is too old or survey questions that may have changed over time. The total number of 
participants was 17,813. We will exclude participants: who have not injected in the past year, who 
have done the survey before, or who are aged under 16 or over 64, resulting in a dataset of 11,371. 
Data from the 2018 survey may be added when it becomes available (anticipated May 2018). 
A full list of variables envisaged in this study is given in the appendix. 
Descriptive analysis 
We will report the prevalence of risk factors, protective factors and incarceration by ever-homeless 
and never-homeless status, using direct standardisation to adjust for possible differences in the age 
and sex profile of the groups (with never-homeless group as the reference). 
Primary analysis 
We will use logistic regression with Hepatitis C exposure (measured as antibody positive in a dried 
blood spot test) as the dependent variable and homelessness as the main independent variable. 
Based on existing literature, we anticipate that homelessness will be positively associated with 
Hepatitis C exposure. We will add blocks of risk factors and protective factors to test whether these 
variables explain any difference in Hepatitis C exposure. We anticipate that risk factors will be added 
as shown in table 1. 
 
Table 1. Example results table: odds ratio of Hepatitis C exposure (outcome) comparing ever-
homeless and never-homeless PWID 
 
Model Odds ratio 95% CI % Change in OR 
1: age + sex 1.5 1.2-1.9 - 
2: model 1 + frequency and duration 1.3 1.1-1.8 13% 
3. model 1 + drugs injected    
4. model 1 + sharing    
5. model 1 + high risk injecting sites    
6. model 1 + all injecting risk variables    
7. model 1 + uses needle exchanges    
8. model 1 + opiate substitution therapy    
9. model 1 + all protective factors    
10. model 1 + incarceration    
11. fully adjusted    
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Secondary analysis 1: joint effects of homelessness and incarceration on hepatitis C exposure 
 We will create a new variable that places participants in four groups: never homeless and never 
incarcerated (reference group); ever-homeless and never incarcerated; never-homeless and ever 
incarcerated; and ever-homeless and ever-incarcerated. We will fit a logistic regression model with 
hepatitis C exposure as the dependent variable and the new variable as the main exposure, adjusting 
for age and sex. This analysis will show whether homelessness and incarceration interact on the risk 
of hepatitis C. We will also fit a model with an interaction term and use a likelihood ratio test 
(comparing with nested model 10 in table 1) to report the significance of the interaction. 
Secondary analyses 2: among those with hepatitis C exposure, how does care differ between 
homeless and non-homeless PWID? 
Among those with evidence of hepatitis C exposure, we will report the proportions that have tested, 
know their status and have had contact with a hepatitis specialist. These proportions will be 
stratified by homelessness status and presented in a ‘cascade’. Differences between proportions at 
each stage will be tested using chi-square tests. The cascade will be presented for the whole sample, 
and also stratified by (a) participants in survey years pre- and post-2014, to see if development of 
direct acting antiviral therapy is associated with improved diagnosis and care and (b) those with 
experience of incarceration, to see if opt-out testing in prisons is associated with improved diagnosis 
and care. 
 
Example of ‘care cascade’ 
 
Ethics 
UAMS has multisite ethics approval. This will be a secondary analysis of anonymised data and further 
ethics consideration is not required. 
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Appendix: UAMS variables 




Survey Year of survey NA Pre vs. post 2014 (i.e. 2012/13/14; 2015/16/17) 
 Government Office 
Region 
NA London / South East / Wales, etc. 
Demographics Age group 2 16-24 / 25-34 / 35-44 / 45-54 / 55-64 
 Sex 3 Male / Female 
Injecting risk Duration of 
injecting (years) 
1b, 2, 10 
 
We will calculate a continuous variable 
 Injected in the past 
month 
11 Yes / No 
 Drugs injected 10 / 11 All options. We will process into 3 binary variables: opiates 
(heroin / methadone), stimulants (crack, cocaine, amphetamine), 
other (ketamine, mephedrone, other), and then to a single 
variable showing combinations (e.g. opiates+stimulants)  
 Received used 
equipment – past 
year/month 
10 / 11 Yes / No 
 Ever received used 
equipment 
6 Yes / No 
 High risk injecting 
sites 
11 All options. We will process into a binary variable: Yes (hands, 
groin, feet, neck) / No / NA (for those not injecting in past 28 
days) 
 Frequency of 
injecting 
11 Continuous – number of days in the past month 
Homelessness Ever homeless 22 No / Yes more than a year ago / Yes past year / Yes currently 
Hep C Hep C antibody + 
from dried blood 
spot 
NA Positive / negative 
 Hep C test in past 20 Yes / No 
 Result of last Hep C 
test (self-report) 
20 Positive / Negative / Awaiting  
(For 2017 onward, current/past/not sure will be grouped as 
positive) 
 Seen hepatitis 
nurse / doctor 





7 Yes / No 
 Needle exchange 
coverage 
5 Number of needles collected in past month. From 2017, 
calculated from number of visits * typical number collected. 
Anticipate using simpler variable (used in past year) because (a) 
this is more consistent; (b) high coverage may reflect risk (a lot of 
injections) or protection (a lot of clean needles) 
 Used needle 
exchange in past 
year 
5 Yes / No 
Incarceration Number of times in 
prison 
21 Continuous variable (0+), created from ‘ever in prison’ (yes / no) 
and number of times in prison 
 Ever injected in 
prison 
21 Yes / no 
 
